inhibition of presynaptic cholinergic signaling by stimulation of presynaptic muscarinic type 2 receptors and nonphysiologic, tonic stimulation of postsynaptic nicotinic and muscarinic receptors.⁶ Despite these limitations, mobility benefits of AChEIs have been reported in PD.⁷

Preliminary data in animal studies suggest that drugs that selectively stimulate $\alpha 4\beta 2$ (*) nicotinic receptors not only have excellent entry into the brain but also may improve mobility functions in rats with dual dopaminergic and cholinergic lesions.⁸ Such selective agonists are superior to the nonselective nicotine mother drug because nicotine interferes with the phasic cholinergic activity that is essential for cognitive function.⁹ Further investigation of this class of drugs to treat mobility problems in PD is necessary.

© 2014 American Academy of Neurology

1. Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. *Neurology* 2013;81:1611–1616.
2. Potter-Nerger M, Volkmann J. Deep brain stimulation for gait and postural symptoms in Parkinson's disease. *Mov Disord* 2013;28:1609–1615.
3. Assal F, Allali G, Kressig RW, et al. Galantamine improves gait performance in patients with Alzheimer's disease. *J Am Geriatr Soc* 2008;56:946–947.
4. Montero-Odasso M, Wells J, Borrie M. Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. *J Am Geriatr Soc* 2009;57:359–360.
5. Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2005;76:315–319.
6. Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. *Neuropsychopharmacology* 2011;36:52–73.
7. Litvinenko IV, Odinak MM, Mogil'naya VI, et al. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). *Neurosci Behav Physiol* 2008;38:937–945.
8. Kucinski A, Paolone G, Bradshaw M, et al. Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation. *J Neurosci* 2013;33:16522–16539.
9. Howe WM, Ji J, Parikh V, et al. Enhancement of attentional performance by selective stimulation of $\alpha 4\beta 2$ (*) nAChRs: underlying cholinergic mechanisms. *Neuropsychopharmacology* 2010;35:1391–1401.

CORRECTION

Tumefactive MS lesions under fingolimod: A case report and literature review

In the article “Tumefactive MS lesions under fingolimod: A case report and literature review” by G. Pilz et al. (*Neurology*® 2013;81:1654–1658), there is an error in the description of figure B.c. The description should have read, “Follow-up MRI 6 months later: a new large T2 hyperintense lesion with perifocal edema is seen in the right frontal white matter which shows ring-like gadolinium enhancement (lower panel).” The authors regret the error.

Neurology®

Tumefactive MS lesions under fingolimod: A case report and literature review

Neurology 2014;82;1569

DOI 10.1212/WNL.0000000000000442

This information is current as of April 28, 2014

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/82/17/1569.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2014 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.